A examine printed in JAMA Network Open up emphasizes the discrepancy involving what it charges to create copyright as well as the retail price ranges sufferers encounter. Despite the low creation prices, Novo Nordisk hasn't publicly disclosed unique figures for copyright or its other products, Wegovy.Novo Nordisk is involved with federal government